Qingdao's venture capital circle is set to gain a substantial injection of long-term capital.

On September 24, China Life announced plans to contribute no more than 4.5 billion yuan to establish the Qingdao Chengxin Zhida Equity Investment Center (Limited Partnership) (hereinafter referred to as "Chengxin Zhida"), focusing on high-quality unlisted equity in the artificial intelligence and semiconductor sectors.

This marks China Life's fourth sci-tech innovation equity investment to land this year. From the Yangtze River Delta and Fujian to Tianjin and now Qingdao, the four investments announced by the 8-trillion-yuan-asset China Life total approximately 16 billion yuan in committed capital.

Unlike short-term financial capital seeking rapid exits, insurance funds naturally possess long-cycle characteristics. This fund, registered in Qingdao, is clearly attractive not merely for the several billion yuan of capital itself.

When a leading domestic insurance capital places its northern hard-tech investment vehicle in Qingdao, it signals more than anything that "patient capital" and the city's AI and semiconductor industries are beginning to connect in both directions.

A 4.5 Billion Yuan Insurance Capital "Targeted Long-Term Commitment"

This time, China Life is not directly buying stocks but acting as a limited partner in a fund. The total subscribed capital of all partners is planned to not exceed 6 billion yuan, with China Life contributing the lion's share (no more than 4.5 billion yuan). Guoshou Chengda (Shanghai) Healthcare Equity Investment Management Co., Ltd. will serve as GP with a subscription of no more than 200 million yuan, while Wuxi Guoshou Chengda Equity Fund will subscribe no less than 200 million yuan, with other investors making up the remaining 1 billion yuan or more. The manager will be Guoshou Equity Investment Co., Ltd.

The fund term is six years, and its direction is clear—artificial intelligence and semiconductors, focusing on high-quality unlisted enterprise equity with core technological barriers, broad domestic substitution space, and outstanding long-term growth certainty in the industrial chain.

Placed within China Life's rhythm this year, the Qingdao deal is actually the "fourth shot." In January, China Life landed a Yangtze River Delta sci-tech innovation fund with total scale exceeding 5 billion yuan in Shanghai, covering three major tracks: artificial intelligence, integrated circuits, and biomedicine; in March, it launched a Fujian S-fund specifically providing follow-on liquidity for existing sci-tech investments through secondary share transactions; in July, it established a Tianjin semiconductor special fund, with nearly all capital directed toward semiconductor industry enterprises.

Connecting these four projects, the layout across the Yangtze River Delta, the southeastern coast, and northern industrial strongholds is clearly visible.

Behind such sustained increases is insurance capital's clear judgment of the long-term value of the hard-tech track.

According to China Life's 2026 semi-annual report, total investment income in the first half reached 314.5 billion yuan, up 146.7% year-on-year, with net profit attributable to shareholders of the parent company exceeding 130 billion yuan, a year-on-year increase of 228.6%. As of the end of June, China Life's investment scale in new quality productive forces had already exceeded 540 billion yuan, with a compound annual growth rate of 30%, covering direct equity investment, PE funds, fund of funds, M&A funds, S transactions, and other investment modes.

In this announcement, China Life stated that establishing Chengxin Zhida is both a response to deployment calls and support for emerging pillar industries, as well as an optimization of insurance asset allocation to capture long-term growth dividends from hard tech.

There is a key detail here: the fund being registered in Qingdao does not mean that all of China Life's 4.5 billion yuan will only be invested in local Qingdao enterprises.

The registration location of an equity investment fund is the location of the fund's legal entity, while investment targets can be qualified sci-tech companies nationwide. This is also common practice for many large industrial funds. However, the choice of registration location itself is a signal.

Capital Entering Qingdao: Where Are the Opportunities?

Chengxin Zhida's investment scope is nationwide, but the fund landing in Qingdao will still bring tangible linkage opportunities to the city's industries.

Today, Qingdao's AI and semiconductor industries already have a solid foundation. In the integrated circuit field, the Qingdao Integrated Circuit Industrial Park focuses on developing the full industry chain including IC manufacturing, equipment, packaging and testing, and R&D design, with advanced packaging being a distinctive advantageous segment. As of now, the park has attracted more than 60 key enterprises with total investment of 196.9 billion yuan.

In the AI track, relying on terminal leaders such as Haier and Hisense, combined with computing power, sensing, and industrial scenarios, Qingdao possesses a large number of implementation scenarios in intelligent manufacturing, smart home appliances, and marine digitalization. These scenarios are precisely the testing grounds that many chip and AI startups need most.

Compared with domestic sci-tech innovation strongholds, cities in the Yangtze River Delta have advantages in high startup density, complete upstream and downstream supporting facilities, ample capital supply, and a concentration of early-stage projects; Shenzhen's semiconductor and AI enterprises are close to the consumer electronics terminal market with rapid industrial chain response speeds.

Northern cities generally have a shortcoming: relatively little early-stage equity investment capital. Many hard-tech enterprises have developed their technology but struggle to obtain subsequent long-term funding, and projects easily get stuck in the pilot testing and industrialization stages.

Hard-tech R&D cycles are lengthy—from sample to mass production often takes many years, with no short-term profits visible. Ordinary market-oriented funds often dare not take heavy positions, which is exactly where insurance capital can fill the gap.

Qingdao's industrial advantage lies in its rich industrial scenarios. Chips, large models, and AI algorithms must ultimately land in real industries for validation. Many non-local portfolio companies, after receiving funding from Chengxin Zhida, will have the opportunity to connect with Qingdao's manufacturing enterprises, marine equipment, rail transit, and smart home scenarios to conduct product validation and pilot implementation here.

Capital can bring industrial resources, and local scenarios in turn attract sci-tech enterprises to land, forming a two-way flow between capital and industry. This is the logic of "investment-driven attraction." It is not necessarily that China Life's 4.5 billion yuan will be directly invested in Qingdao enterprises, but with the capital vehicle placed here, the industrial connection window is built here.

Moreover, for insurance capital to truly dare to invest, be willing to invest, and be able to invest, three aspects of supporting measures are needed: fostering an ecosystem for long-term money and long-term investment, improving assessment and fault-tolerance mechanisms, and opening up the entire chain of fundraising, investment, management, and exit.

Hard-tech investment has a high failure rate, and technological routes face uncertainty. If assessments focus on short-term returns, long-term capital will find it hard to act freely. As a stabilizer of the capital market, insurance funds are suited to accompany sci-tech enterprises through technology iteration cycles.

Qingdao has already simultaneously built a six-in-one multi-level exit channel covering domestic and overseas listings, M&A and restructuring, S-fund share transfers, regional equity market circulation, physical stock distribution, and state-owned property rights listing transfers, improving the local venture capital ecosystem and precisely matching insurance capital's demands.

However, China Life's planned subscription of 4.5 billion yuan is only a subscribed amount, not funds fully in place immediately. The fund's registration and landing does not equal immediately bringing large-scale output value in the short term.

Equity investment is a slow business. From capital subscription and completed paid-in capital to project due diligence, investment decisions, and landing, it is a process lasting several years with a very long return cycle. It is not a one-time industrial subsidy but a market-oriented capital choice. Whether an enterprise can obtain investment ultimately depends on technological barriers, product implementation capability, and commercialization prospects.

But the real value of this matter lies in its demonstration effect. As one of the largest insurance institutions in China, China Life choosing to register this sci-tech innovation fund in Qingdao is equivalent to releasing a signal to the market: Qingdao's venture capital business environment and hard-tech industrial soil can accommodate national-level long-term capital.

It will attract more insurance funds and national-level industrial funds to consider placing fund entities and regional investment platforms in Qingdao. As more patient capital gathers here, local sci-tech enterprises will have more financing options, no longer relying solely on government guidance funds and short-term venture capital.

From the perspective of urban development, cultivating new quality productive forces is not just about building factories and attracting projects—the capital ecosystem is equally infrastructure. AI and semiconductors are capital-intensive tracks, with high R&D investment per enterprise and long return cycles, requiring capital that can withstand the test of time. The entry of insurance capital will add an important piece to Qingdao's sci-tech innovation ecosystem.